Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY24 Earnings Presentation
16 slides from Alembic Pharmaceuticals's earnings presentation, Aug 4, 2023
Slide 1: Cover letter to stock exchanges
Date: 4th August, 2023 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573 N
Slide 2: Alembic Pharmaceuticals Limited Investor presentation – June 2023
Alembic Pharmaceuticals Limited Investor presentation – June 2023 BSE & NSE: APLLTD 1
Slide 3: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL
Slide 4: Financial Highlights
Financial Highlights Particulars Q1 FY24 Q1 FY23 Growth FY23 INR Bn Net Sales 14.86 12.62 18% 56.53 EBIDTA Pre R&D 3.19 2.43 31% 13.01 Margin % 21% 19% 23% R&D (Including Aleor's accelerated 1.19 2.61 -55% 7.22 amortization) R&D (Excluding Aleor's accelerated 1.19 1.46 -19% 5.66 amortization) R&D %
Slide 5: Revenue snapshot – Q1FY24
Revenue snapshot – Q1FY24 INR Bn Key Highlights : Business Q4FY23 Q1FY24 Q1FY23 Y-o-Y Q-o-Q Formulations India Branded Business : India Branded Business recorded 9% India 4.90 5.24 4.80 9% 7% growth with topline of Rs 524 crores for Q1 FY24. Specialty US 3.54 3.90 3.67 6% 10% Ex-US 2.49 2.66 1.82 46
Slide 6: Branded Business
Branded Business Revenue – Q1 FY24 INR Bn Revenue – Last 5 Years CAGR - 11% INR Bn 20.6 5.24 19.3 4.80 0.80 0.72 15.0 1.33 13.8 14.3 Vet 1.19 Acute Speciality 2.89 3.12 Q1FY23 Q1FY24 FY19 FY20 FY21 FY22 FY23 Marketing organization Key achievements ➢ 5000+ MRs ➢ India Branded Business recorded 9% gro
Slide 7: Branded Business
Branded Business Top Brands with rank and MS% Prescription Business 1311 Leading Brands Other Leading Brands 1150 Rank MAT Rank MAT BRANDS MAT Jun 23 BRANDS MAT Jun Jun 23 Jun 23 MS% 23 MS% YTD May 22 AZITHRAL 1 32.3 ELATA 1 42.3 TELLZY 5 4.8 VEHYCAL-XT 4 7.1 YTD May 23 WIKORYL 3 10.3 ESTROPLUS 2 39
Slide 8: Therapy-wise Performance Q1 FY24
Therapy-wise Performance Q1 FY24 Q1 FY24 Q1 FY23 IPM Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Gynecology 6 3.1 19 16 22 2.8 37 45 Cardiology 10 1.8 8 9 0 1.9 10 11 Gas
Slide 9: Animal Health Business
Animal Health Business Revenue - YTD Mar for Major 5 brands INR Cr Revenue – Q1FY24 CAGR - 26% INR Cr 166.7 139.9 111.0 83.3 Animal Health 80 72 Q1FY23 Q1FY24 FY20 FY21 FY22 FY23 Key achievements ➢ Leader in Hematinic Market covering Sharkoferrol Brand ➢ Leader in Anti Biotic Market covering Moxel,
Slide 10: US Generic
US Generic INR Bn Revenue – Q1 FY24 INR Bn Revenue – Last 5 Years CAGR - 5% 21.63 19.76 3.90 16.66 3.67 15.72 12.88 Q1FY23 Q1FY24 FY19 FY20 FY21 FY22 FY23 Approved ANDAs Injectable 10 Inhalation Ophthalmic 16 2 ➢ Well-established US front end with strong customer base ➢ 6 products launched in Q1FY24
Slide 11: Ex-US Generics
Ex-US Generics Revenue : Q1 FY24 INR Bn Revenue – Last 5 Years INR Bn 2.66 CAGR - 15% 1.82 8.52 7.79 7.75 Q1FY23 Q1FY24 4.94 4.97 ➢ Recorded 46% growth led by robust demand across markets. ➢ Ex-US driven by partnership. Delivered 15% CAGR over last 5 years. ➢ Presence in following key markets - Euro
Slide 12: API
API Revenue : Q1 FY24 INR Bn Revenue – Last 5 Years INR Bn CAGR - 11% 3.05 11.66 2.33 9.55 9.39 7.71 Q1FY23 Q1FY24 7.08 ➢ Growth of 31% on QoQ basis is led by high off-take and better product mix in Q1. ➢ 131 Cumulative DMF filings with the US FDA. ➢ Expect steady growth for this business. ➢ Future
Slide 13: R&D
R&D Dosage form wise ANDA approval and Launch R&D Capabilities Q1FY24 Formulation : Vadodara and Hyderabad Dosage Forms Approval* Launch OSD 2 2 API : Vadodara and Hyderabad Injectable - Gen 2 1 Injectable - Onco - 2 Bio Centre : Vadodara Ophthalmology 1 - Dermatology - 1 Other - - *Includes tentati
Slide 14: State of the art facilities and infrastructure
State of the art facilities and infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Mar’20 Oncology Oral Solids Jun’19 F2 – Panelav Oncology Injectables Oct’22 F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Mar’23 F4 –
Slide 15: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn 56.53 INR Bn 53.93 53.06 16.31 11.78 46.06 39.35 12.13 8.29 10.53 # 8.75 6.65 # 7.79 # 5.84 4.97 # FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 EBIDTA margin % Capex ROCE % INR Bn 30 6.97
Slide 16: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Q1 FY24 Earnings Presentation on 6ix